Want to see TSE:VM full AI Analyst Report?
VM Stock Chart & Stats
C$0.17
>-C$0.01(-5.56%)
At close: 4:00 PM EST
C$0.17
>-C$0.01(-5.56%)
Day’s Range― - ―
52-Week RangeC$0.07 - C$0.20
Previous CloseN/A
Volume12.11K
Average Volume (3M)72.03K
Market Cap
C$37.35M
Enterprise ValueC$14.81
Total Cash (Recent Filing)C$441.87K
Total Debt (Recent Filing)C$40.00K
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
Nov 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding226,342,350
10 Day Avg. Volume61,621
30 Day Avg. Volume72,034
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)21.82
Price to Sales (P/S)2339.21
P/FCF Ratio-9.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt reduces financial risk and interest burden, giving management flexibility to prioritize product qualification and commercial ramp without near-term debt servicing constraints. This structural balance sheet strength supports surviving development timelines and negotiating non-debt funding.
Early Revenue TractionA 52.6% TTM revenue increase from a low base demonstrates emerging commercial traction for processed barite products. Sustained top-line growth, if continued, underpins scale economics, supports margin improvement initiatives, and validates market acceptance over the next several months.
Specialized Pharma-Grade FocusConcentrating on pharmaceutical-grade barium sulfate for medical imaging targets a higher-barrier, higher-value niche. Regulatory qualification and processing know-how create durable competitive advantages and justify premium pricing potential and strategic partnerships over a multi-month commercialization horizon.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow means the company is consuming cash to run core operations. This structural cash burn necessitates external financing or dilution, constrains investment in processing capacity and regulatory clearance, and limits ability to scale commercially.
Deep Negative ProfitabilityDeeply negative gross profit indicates costs materially exceed current revenues, not just one-off items. Persistent negative margins and large net losses signal an unprofitable cost structure that must be fixed via scale, product mix, or pricing to avoid prolonged capital drains and enable sustainable operations.
Eroding Equity BaseSharp decline in shareholder equity reflects cumulative losses and reduces the financial cushion for operating setbacks. A weakened capital base limits access to non-dilutive funding, raises dilution risk from future equity raises, and constrains strategic optionality over the medium term.
Voyageur Pharmaceuticals News
VM FAQ
What was Voyageur Pharmaceuticals’s price range in the past 12 months?
Voyageur Pharmaceuticals lowest stock price was C$0.07 and its highest was C$0.20 in the past 12 months.
What is Voyageur Pharmaceuticals’s market cap?
Voyageur Pharmaceuticals’s market cap is C$37.35M.
When is Voyageur Pharmaceuticals’s upcoming earnings report date?
Voyageur Pharmaceuticals’s upcoming earnings report date is Nov 02, 2026 which is in 80 days.
How were Voyageur Pharmaceuticals’s earnings last quarter?
Voyageur Pharmaceuticals released its earnings results on Jul 24, 2026. The company reported -C$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Voyageur Pharmaceuticals overvalued?
According to Wall Street analysts Voyageur Pharmaceuticals’s price is currently Overvalued.
Does Voyageur Pharmaceuticals pay dividends?
Voyageur Pharmaceuticals does not currently pay dividends.
What is Voyageur Pharmaceuticals’s EPS estimate?
Voyageur Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Voyageur Pharmaceuticals have?
Voyageur Pharmaceuticals has 226,342,350 shares outstanding.
What happened to Voyageur Pharmaceuticals’s price movement after its last earnings report?
Voyageur Pharmaceuticals reported an EPS of -C$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Voyageur Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:VM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. specializes in the creation of mineral-based active pharmaceutical ingredients (APIs). The company aims to produce radiocontrast agents utilizing barium and iodine, along with pharmaceutical products derived from bromine. It possesses complete ownership of three barium sulfate deposits in British Columbia, Canada, two of which are of a quality appropriate for the pharmaceutical barite sector. Furthermore, Voyageur holds stakes in a valuable brine project in Utah, United States, known for its high concentrations of iodine, lithium, and bromine. The company transitioned from its previous name, Voyageur Minerals Ltd., to Voyageur Pharmaceuticals Ltd. in December 2019. Its corporate headquarters are located in Calgary, Canada.